Dipeptidyl peptidase-4 (DPP-4) inhibitors exert hypoglycemic effects by inhibiting the degradation of glucagon-like peptide-1 (GLP-1) in patients with type 2 diabetes mellitus [95]. This evidence concerns the gene GCG and diabetes mellitus.